Company news

Monopar Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

August 2, 2021

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

July 11, 2021

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

June 23, 2021

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

June 2, 2021

Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

May 31, 2021

Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic

May 25, 2021

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

May 23, 2021

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

May 12, 2021

Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

March 29, 2021

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates

March 24, 2021

Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery

March 1, 2021

Monopar Therapeutics to Present at Upcoming Investor Conferences

February 23, 2021

Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations

February 17, 2021

Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

February 15, 2021

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

February 10, 2021

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

February 8, 2021

Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

December 21, 2020

Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19

December 9, 2020

Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

December 7, 2020

Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

November 11, 2020

Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®

November 8, 2020

Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

September 13, 2020

Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19

September 8, 2020

Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19

August 18, 2020

Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology

August 11, 2020

Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19

August 9, 2020

Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates

August 5, 2020

Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR

June 29, 2020

Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19

June 15, 2020

Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates

May 6, 2020

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates

March 26, 2020

Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma

February 17, 2020

Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock

December 22, 2019

Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters

December 19, 2019

Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering

December 17, 2019

← Newer news releases

Decks

The 5 newest of 7 decks. Every deck is listed under its year.